Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Nov
20
Today In Oncology
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo